Kaliphos

Dipotassium Phosphate and Potassium Dihydrogen Phosphate, the active ingredients in Kaliphos, are an electrolyte solution presented as a solution for injection for intravenous use. It provides phosphate replacement and corrects electrolyte imbalances in patients who require intravenous therapy.

GNH USA supplies Kaliphos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kaliphos is an intravenous electrolyte solution used to address conditions where phosphate and potassium balance are disrupted. - Phosphate replacement: restores serum phosphate levels in patients with hypophosphatemia. - Electrolyte imbalance correction: normalises potassium and phosphate concentrations during acute illness. - Peri‑operative management: supports metabolic needs of patients undergoing major surgery.

Kaliphos may cause a range of adverse reactions, most of which are related to rapid changes in serum electrolytes.

Common Side Effects: - Hyperphosphatemia: elevated serum phosphate levels. - Hyperkalemia: increased potassium concentration. - Infusion site irritation: redness or discomfort at the catheter. - Mild hypotension: transient drop in blood pressure. - Nausea or headache.

Serious or Rare Side Effects: - Severe hyperphosphatemia leading to calcium‑phosphate precipitation. - Cardiac arrhythmias due to electrolyte shifts. - Anaphylactic reaction: rash, bronchospasm, hypotension. - Metabolic acidosis. - Acute renal failure.

When using Kaliphos, clinicians should consider patient‑specific factors and monitor laboratory values. - Renal impairment: monitor serum phosphate and potassium closely. - Cardiac disease: watch for arrhythmias during infusion. - Pregnancy: use only if potential benefit justifies the risk. - Concomitant potassium supplements: avoid additive hyperkalemia. - Infusion rate: administer according to prescribed protocol to prevent rapid electrolyte shifts. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kaliphos can interact with other medicines that affect phosphate or potassium balance.

Major Interactions (Avoid): - Calcium‑containing solutions: may precipitate phosphate and reduce efficacy. - Aluminum‑containing antacids: can bind phosphate and diminish replacement. - High‑dose vitamin D analogues: increase risk of severe hyperphosphatemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: may enhance potassium loss. - ACE inhibitors or ARBs: can potentiate hyperkalemia. - Blood transfusions (citrate): may affect calcium and phosphate homeostasis.